151 – 160 of 363
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2016
-
Mark
Radioimmunotherapy for Prostate Cancer-Current Status and Future Possibilities.
(
- Contribution to journal › Scientific review
-
Mark
Analytical Validation of the Automated Bone Scan Index as an Imaging Biomarker to Standardize the Quantitative Changes in Bone Scans of Patients with Metastatic Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Low β2-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism.
(
- Contribution to journal › Article
-
Mark
The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Oncologic and functional outcomes 1 year after radical prostatectomy for very low risk prostate cancer. Results from the prospective LAPPRO trial.
(
- Contribution to journal › Article
-
Mark
The Proteome of Primary Prostate Cancer.
(
- Contribution to journal › Article
-
Mark
Preparedness for side effects and bother in symptomatic men after radical prostatectomy in a prospective, non-randomized trial, LAPPRO
(
- Contribution to journal › Article
-
Mark
Expression of the TPa and TPβ isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer : Clinical significance and diagnostic potential
(
- Contribution to journal › Article
-
Mark
Psychological Well-being and Private and Professional Psychosocial Support After Prostate Cancer Surgery : A Follow-up at 3, 12, and 24 Months After Surgery
(
- Contribution to journal › Article
-
Mark
Preclinical Characterization of 3β-(N-Acetyl l -cysteine methyl ester)-2aβ,3-dihydrogaliellalactone (GPA512), a Prodrug of a Direct STAT3 Inhibitor for the Treatment of Prostate Cancer
(
- Contribution to journal › Article